Hims & Hers Health, Inc. (HIMS)
Hims & Hers Stock Declines 3.1% in 3 Months: Is it a Buy Now?
HIMS is expanding its health and wellness products and services and increasing its focus on AI to solidify its footing. However, macro challenges may hurt performance.
Hims & Hers: Growth, Strategic Partnerships, And Operational Leverage (Upgrade)
Hims & Hers Health's rapid revenue and subscriber growth, plus improving cash generation, highlight strong business momentum and brand strength. Gross margins have declined due to lower-margin obesity products, but SG&A as a percentage of revenue is improving, supporting better operating leverage. The recent Novo Nordisk collaboration and capital raise position Hims for expansion, though reliance on GLP-1 drugs and competition are key risks.
Hims & Hers Health, Inc. (HIMS) is a Great Momentum Stock: Should You Buy?
Does Hims & Hers Health, Inc. (HIMS) have what it takes to be a top stock pick for momentum investors? Let's find out.
Hims & Hers: Still Undervalued For These 2 Reasons
Hims' operating leverage was outstanding at 5:1 over revenue growth. This is irrefutable proof of a scalable business. Hims' new TAMs should provide billions to the top line, hundreds of millions to the bottom, and dollars to EPS. Hims is likely a decade-plus ahead of competitors at this point with 'The Hims Trinity.'
Hims & Hers: Short-Lived Turbulence To Be Followed By New Phase Of Profitable Growth
Hims & Hers delivered impressive Q1 2025 results, with 111% y/y revenue growth and 38% y/y subscriber growth, driven by strong uptake of personalized GLP-1 offerings. Despite a projected Q2 revenue decline due to product transitions, management reaffirmed full-year 2025 revenue guidance of $2.3–2.4B and raised adj. EBITDA guidance to $295–335M. Long-term growth prospects remain strong, with a target of $6.5B+ revenue and $1.3B+ adj. EBITDA by 2030, driven by TAM penetration, new specialties, and AI integration.
Hims & Hers: Wegovy Deal Opens New Growth Chapter - Missed The Rally? Selling Puts Could Yield 30%
Hims & Hers Health rebounded from a 60% stock drop by partnering with Novo Nordisk, offering Wegovy at a competitive price, boosting accessibility and growth. Q1 earnings were exceptional with 111% YoY revenue growth and a 345% increase in net income, highlighting a sustainable and resilient business model. The company's personalized healthcare approach and new product launches, like low testosterone and menopause support, are driving subscriber growth and higher revenue per subscriber.
Is Trending Stock Hims & Hers Health, Inc. (HIMS) a Buy Now?
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: The Road To Blue Chip Status
Personalized subscribers grew 136% YoY, reflecting a fundamental shift towards precision medicine. Despite declining gross margins, HIMS achieved 13pp of operating leverage in Q1. This is by far HIMS' best quarter to date. The markets need to put some respect on Andrew Dudum and his world-class team.
Hims & Hers Soars Again--Explosive Growth Meets Lofty Expectations
Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo Nordisk partnership. Despite trading at a high valuation, technical indicators suggest continued short-term momentum, with potential for a pullback near February highs. The company's evolution from a telehealth startup to a health-tech giant showcases its strong growth, profitability, and expanding service offerings.
Hims & Hers: 2030 Guidance Indicates Big Upside
Management's 2030 guidance includes $6.5 billion in revenue and $1.3 billion in adjusted EBITDA, focusing on personalized healthcare and geographic expansion. Anticipating management's guidance for 2025 and 2030, Hims & Hers could be undervalued by up to 62%. Apart from the guidance, the company needs to achieve growth rates in the mid-teens% to justify the current valuation.
Surging Earnings Estimates Signal Upside for Hims & Hers Health (HIMS) Stock
Hims & Hers Health (HIMS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Hims & Hers Health: Healthcare Disruptor Building A Durable Moat (Initiate With Buy)
Hims & Hers Health reported strong Q1 '25 earnings, with 111% YoY sales growth and 38% subscriber growth. The company boasts over a 70% gross margin, 90% recurring revenue, and a compelling flywheel effect driven by machine learning and big data analytics. Risks include the untested business model, potential legal issues, and the complexity of international expansion, but the growth potential presented far outweighs these concerns.
